Contexto sectorial
Genmab AS [GMAB]
Última actualización 24 Jun 2026 @ 16:00 (Exchange is closed)
Último: $25.87
-0.29%
-1.22 (↓)
GaG Algo Score™
v1.0
Corto
-1.22 (↓)
Medio
-2.35
Largo
-1.67 (↑)
COMPRAR
65.31%
rentabilidad 2.57%
VENDER
72.00%
rentabilidad 12.09%
Línea
Datos pivot
Estadísticas pivot
| Métrica | Promedio | Mediana | Desv. est. |
|---|---|---|---|
| Ganancia % | 7.18% | 6.82% | 1.44% |
| Pérdida % | -10.14% | -10.14% | 3.13% |
| Duración | 11.0d | 13d | 7.5d |
| Pivots encontrados | 6 |
| Tramos ganancia/pérdida | 5 (3 Ganancia / 2 Pérdida) |
| Último pivot | Top @ $25.94 el 2026-06-23 |
| Cambio desde el último pivot | $0.00 (0.00%) |
Predicción del próximo pivot Último: $25.87
| Próximo tipo previsto | Bottom |
| Precio previsto (prom.) | $23.31 |
| Precio previsto (mediana) | $23.31 |
| Rango de precio previsto (~68%) | $22.50 - $24.12 |
| Cambio al objetivo promedio | $-2.55 (-9.88%) |
| Fecha prevista (prom.) | 2026-07-04 |
| Rango de fechas previsto (~68%) | 2026-06-26 - 2026-07-11 |
| Base | Based on 2 historical losses (Avg: -10.14%, Median: -10.14%, StdDev of Abs: 3.13%) and duration (Avg: 11.0 days, StdDev: 7.5 days) |
| Nota | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Genmab AS gained modestly, up 1.29%.
Genmab AS (GMAB) stock price moved up modestly on Tuesday after the stock rose $0.330 (1.29%) from the previous session on normal volume. The stock showed moderate relative strength, staying flat or rising slightly while the NASDAQ fell -0.43%. Yesterday's trading volume was 1.26M shares, worth about $32.72M. This represents 331 800 shares less than the day before. Volume was close to the 10-day average of 1.50M shares.
Genmab AS signals
There is no conclusive signals given from RSI. The price is above the short-term average yet below the long-term average, with the short-term average still below the long-term average; signals are mixed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-16.7%), medium- (-16.7%), and long-term (-16.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Genmab AS Support & Resistance Levels
The stock is trading above the closest support level at $25.70. approximately $0.240 (0.93%) away. This suggests it is currently acting as a floor, reacting up from support.The sup dis das support s125.7 -
Genmab AS Evaluation
- Corto puntuación: -1.22
- Medio puntuación: -2.35
- Largo puntuación: -1.67
Mapa de relación
Resumen de correlación
<span style="background-color: lightgreen">Undervalued: <i class="arrow arrow-up"></i>0.45% <strong>$25.98</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
1.63%
Of outstanding shares
Short float
1.65%
Of tradable float
Days to cover
4.56
Short interest divided by average volume
Squeeze probability
2.60%
-1.10% change
Short interest is worth monitoring, but the setup is not extreme.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
4
EPS misses
5
Avg. surprise
3.56%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-11-06 | - | - | - | - |
| Q2/2025 | 2025-08-14 | - | $0.400 | - | - |
| Q1/2025 | 2025-05-08 | $0.310 | $0.230 | 34.78% | 715.00M |
| Q4/2024 | 2025-02-12 | $0.570 | $0.280 | 103.57% | 891.43M |
| Q3/2024 | 2024-11-06 | $0.290 | $0.320 | -9.38% | 5.54B |
| Q2/2024 | 2024-08-08 | $0.220 | $0.290 | -24.14% | 5.40B |
| Q1/2024 | 2024-05-02 | $0.160 | $0.160 | 0.00% | 4.14B |
| Q4/2023 | 2024-02-14 | $0.360 | $0.340 | 5.88% | 4.68B |
Analyst view
Analyst targets
Consensus
$38.30
Median
$40.00
Low
$32.00
High
$41.50
Recent target updates
News flow
Latest company news
Market coverage
globenewswire.com Capital Increase in Genmab as a Result of Employee Warrant Exercise Jun 16, 2026 globenewswire.com Major Shareholder Announcement Jun 15, 2026 gurufocus.com Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Jun 13, 2026 globenewswire.com Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Jun 13, 2026Company releases
Company context
Company profile
Bolsa:
NASDAQ
Sector:
Healthcare
Industria:
Biotechnology
Currency
USD
Genmab AS a biopharmaceutical company founded in 1999 and headquartered in Copenhagen Denmark specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses The companys commercialized portfolio includes several key products DARZALEX daratumumab a human monoclonal antibody for multiple myeloma MM nonMM blood cancers and AL amyloidosis teprotumumab indicated for thyroid eye disease ofatumumab another human monoclonal antibody used in chronic lymphocytic leukemia CLL and multiple sclerosis Amivantamab for advanced or metastatic gastric or esophageal cancer and nonsmall cell lung cancer NSCLC and tisotumab vedotin which targets cervical ovarian and solid tumors Genmab maintains a robust pipeline of investigational medicines These include GEN1047 DuoBodyPDL1x41BB and DuoBodyCD40x41BB both developed for solid tumors Epcoritamab in development for relapsedrefractory diffuse large Bcell lymphoma and chronic lymphocytic leukemia and HexaBodyCD38 and DuoHexaBodyCD37 aimed at hematological malignancies Furthermore the company has several products in Phase 2 clinical trials Teclistamab for vasoocclusive crises Camidanlumab tesirine for Hodgkin lymphoma and solid tumors JNJ64007957 and JNJ64407564 for MM PRV015 for celiac disease Mim8 for haemophilia A and Lu AF82422 for multiple system atrophy disease In addition to its clinical programs Genmab is advancing approximately 20 active preclinical programs Genmab fosters strategic collaborations to further its research and development efforts It holds a commercial license and codevelopment agreement with Seagen Inc for tisotumab vedotin The company also partners with CureVac AG on the research and development of differentiated mRNAbased antibody products and with AbbVie for the development of epcoritamab Further alliances include BioNTech Janssen Novo Nordisk AS BliNK Biomedical SAS and Bolt Biotherapeutics Inc
Navigation